Low-dose methotrexate in sickle-cell disease: a pilot study with rationale borrowed from rheumatoid arthritis.

BACKGROUND

Inflammation is a major feature of sickle cell disease (SCD). Low-dose methotrexate (MTX) has long been used in chronic inflammatory diseases. This pilot study examined the MTX effect on acute vaso-occlusive pain crises (VOC) in SCD patients.

METHODS

Fourteen adults on hydroxyurea with severe and refractory VOC received one intramuscular injection of 10 mg of MTX per week for 12 weeks. A single weekly dose of 5 mg of leucovorin was administered orally 48 h after each MTX injection. The primary outcome was reduction in number/intensity of acute pain episodes. The secondary outcomes were improvement of quality of life (QOL) and reduction of the inflammatory status.

RESULTS

MTX did not significantly change the median VOC frequency (12 before vs 10.5 during treatment,  = 0.6240) or the median McGill pain index (45 at week 0 vs 39.5 at week 12,  = 0.9311). However, there was a decrease of ≥50% in chronic pain resulting from avascular osteonecrosis (AVN) in 5 out of 7 patients with radiologic evidence of AVN, with the perception of longer pain-free periods. There was a 44.4% median gain in physical function in the SF-36 QOL questionnaire ( = 0.0198). MTX treatment up-regulated two C-X-C motif chemokines (CXCL), CXCL10 ( = 0.0463) and CXCL12 ( < 0.0001), without significant effect on 14 additional plasma inflammatory markers. Adverse events: One individual had fever of unknown origin. Respiratory tract infections were recorded in five patients. Among the latter, one also had dengue fever and another had a central venous line infection and died of pneumonia and septic shock. Three patients with previous history of hydroxyurea-induced hematological toxicity developed low blood platelet counts while receiving simultaneously MTX and hydroxyurea.

CONCLUSIONS

Although MTX did not reduce acute VOC frequency/intensity, it decreased chronic pain and led to QOL improvement. http://www.who.int/ictrp/en/ and http://www.ensaiosclinicos.gov.br, RBR-2s9xvn, 19 December 2016, retrospectively registered.